Cited 30 times in
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승업 | - |
dc.date.accessioned | 2021-09-29T01:24:23Z | - |
dc.date.available | 2021-09-29T01:24:23Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184344 | - |
dc.description.abstract | Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sung Won Lee | - |
dc.contributor.googleauthor | Jonggi Choi | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Young-Suk Lim | - |
dc.identifier.doi | 10.3350/cmh.2021.0179 | - |
dc.contributor.localId | A00654 | - |
dc.relation.journalcode | J00557 | - |
dc.identifier.eissn | 2287-285X | - |
dc.identifier.pmid | 34157830 | - |
dc.subject.keyword | Carcinoma, Hepatocellular | - |
dc.subject.keyword | Efficacy | - |
dc.subject.keyword | Entecavir | - |
dc.subject.keyword | Hepatitis B | - |
dc.subject.keyword | Outcome | - |
dc.subject.keyword | Tenofovir | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 402 | - |
dc.citation.endPage | 412 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, Vol.27(3) : 402-412, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.